title: PI3K inhibitors for cancer treatment: five years of preclinical and clinical research after BEZ235.
authors.affiliation: Novartis Institute for Biomedical Research, Oncology Disease Area, Klybeckstrasse 141, Basel, 4002, Switzerland. sauveur-michel.maira@novartis.com
authors.forename: Sauveur-Michel
authors.initials: SM
authors.lastname: Maira
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D006801:Humans; D007093:Imidazoles / Q000494:pharmacology*; D000081082:Phosphoinositide-3 Kinase Inhibitors; D047428:Protein Kinase Inhibitors / Q000494:pharmacology*; D011494:Protein Kinases / Q000378:metabolism*; D011804:Quinolines / Q000494:pharmacology*
chemical_list: D000970:Antineoplastic Agents; D007093:Imidazoles; D000081082:Phosphoinositide-3 Kinase Inhibitors; D047428:Protein Kinase Inhibitors; D011804:Quinolines; D011494:Protein Kinases